Eli Lilly | LLY - Sales Revenues

Eli Lilly reported $9.35B in Sales Revenues for its fiscal quarter ending in December of 2023.

Sales Change Date
AbbVie USD 14.3B 374M Dec/2023
Abbott USD 9.96B 281M Mar/2024
ALKERMES USD 377.48M 3.46M Dec/2023
Amgen USD 8.2B 1.29B Dec/2023
AstraZeneca USD 12.02B 532M Dec/2023
Baxter International USD 3.88B 177M Dec/2023
Biogen USD 2.29B 96.3M Mar/2024
Bristol-Myers Squibb USD 11.9B 423M Mar/2024
Catalent USD 1.02B 42M Dec/2023
Drreddys Laboratories INR 72.15B 3.35B Dec/2023
Eli Lilly USD 9.35B 145.2M Dec/2023
Gilead Sciences USD 7.12B 64M Dec/2023
GlaxoSmithKline GBP 8.05B 95M Dec/2023
Glaxosmithkline GBP 8.05B 95M Dec/2023
J&J USD 21.38B 15M Mar/2024
Medtronic USD 8.09B 105M Dec/2023
Merck USD 15.8B 1.17B Mar/2024
Neurocrine Biosciences USD 515.2M 16.4M Dec/2023
Novartis USD 11.83B 54M Mar/2024
Novartis USD 11.78B 316M Dec/2023
Perrigo USD 1.16B 33.1M Dec/2023
Pfizer USD 14.25B 1.02B Dec/2023
Prestige Brands USD 282.74M 3.58M Dec/2023
Regeneron Pharmaceuticals USD 3.43B 71.6M Dec/2023
Roche Holding CHF 28.94B 842M Dec/2023
Sanofi EUR 10.92B 1.05B Dec/2023
Sanofi EUR 11.75B 1.26B Dec/2023
United Therapeutics USD 614.7M 5.3M Dec/2023
Zoetis USD 2.21B 62M Dec/2023